Dr. Jennifer Y. Pierce was recruited to MCI from the Medical University of South Carolina, where she served as GYN Oncology Disease Team Leader at Hollings Cancer Center and Associate Professor in Obstetrics and Gynecology. With a degree in medicine from MUSC and degrees in engineering and public health from the University of Virginia – Charlottesville, Dr. Pierce became the first female gynecologic oncologist in South Carolina in 2009. Dr. Pierce serves on the National HPV Roundtable as well as on the cervical cancer and immunotherapy committees for the NRG, the cooperative clinical trials group of the NCI. Dr. Pierce treats patients suffering from gynecologic malignancies, including all medical and surgical aspects.
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)
Patients with Endometrial Carcinoma
A Phase 1 Study of MK-5890 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
Treatment for Advanced Solid Tumors
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors
Treatment for Solid Tumors
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (anti–PD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) - RaPiDS
Treatment for Cervical Cancer
A PHASE III, DOUBLE-BLIND,PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Treatment for Breast Cancer
A Phase II Study of Cabozantinib (XL184) Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
Treatment for Cervical Cancer
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer.
Treatment for Uterine / Vaginal Cancer
As director, Pierce says she fulfills the roles of principal, counselor, recruiter, financial officer, time keeper and registrar for 16 physicians in training.
Dr. Jennifer Young Pierce, professor of Interdisciplinary Clinical Oncology and leader of Cancer Control and Prevention at USA Health Mitchell Cancer Institute, is one of 16 oncologists to be chosen for a leadership development program by the American Society of Clinical Oncology.
USA Health researchers studying HPV vaccination rates in Alabama discovered that counties with higher rates of HPV-related cancers in unvaccinated adults had higher rates of HPV vaccinations among adolescents, according to research presented at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer.
USA Health Mitchell Cancer Institute has launched a statewide campaign called “GO Teal and White” to raise awareness about how to prevent cervical cancer, which is killing more women in Alabama than in any other state in the nation. The campaign will run throughout January, Cervical Cancer Awareness Month.
